Myeloid derived suppressor cells targets for therapy

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Waldron, Todd J ^a,b   Quatromoni, Jon G ^c   Karakasheva, Tatiana A ^a,b   Singhal, Sunil ^c,d   Rustgi, Anil K ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cpg oligodeoxynucleotides (ODN); Curcumin; Cyclophosphamide; Docetaxol; Gemcitabine; Myeloid derived suppressor cells; RNA aptamer

Indexed keywords

3,5,7 TRIHYDROXY 4' EMTHOXY 8 (3 HYDROXY 3 METHYLBUTYL)FLAVONE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APTAMER; ARGINASE 1; BETA INTERFERON; CELECOXIB; CPG OLIGODEOXYNUCLEOTIDE; CURCUMIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOCETAXEL; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; ICARIIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA ANTIBODY; L SELECTIN; MATRIX METALLOPROTEINASE INHIBITOR; PLACEBO; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; SILDENAFIL; TADALAFIL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST TUMOR; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MALIGNANT MESOTHELIOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR MICROENVIRONMENT; WHOLE BODY RADIATION;

EID: 84885956883     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24117     Document Type: Article

References (89)

1. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. American journal of translational research 2012; 4:376-89
2. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; http://dx.doi. org/10.1038/nri1668
3. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; http://dx.doi.org/10.4049/jimmunol.0802740
4. Almand B, Clark JI, Nikitina E, Van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678-89.
5. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; http://dx.doi.org/10.1007/s00262-008-0523-4
6. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348-53; http://dx.doi.org/10.1097/ PPO.0b013e3181eb3358
7. Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012; 4:291-304; http://dx.doi. org/10.2217/imt.11.178
8. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-21; http://dx.doi. org/10.1016/j.ccr.2004.08.031
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; http://dx.doi.org/10.1126/science. 1203486
10. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; http://dx.doi.org/10.1038/ni1102-991
11. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2:293-9; http:// dx.doi.org/10.1038/86297
12. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; http://dx.doi.org/10.1038/ nature06309
13. Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72:3987-96; http://dx.doi.org/10.1158/0008-5472.CAN-12-1337
14. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; http:// dx.doi.org/10.1016/j.immuni.2004.07.017
15. Youn JI, Gabrilovich DI. The biology of myeloidderived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75; http:// dx.doi.org/10.1002/eji.201040895
16. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2:907-16; http:// dx.doi.org/10.1038/ni1001-907
17. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-701; http://dx.doi.org/10.4049/jimmunol. 0900092
18. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91; http://dx.doi.org/10.1111/j.1600-065X.2008.00608.x
19. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689-95.
20. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13:721s-6s; http://dx.doi. org/10.1158/1078-0432.CCR-06-2197
21. Ko JS, Bukowski RM, Fincke JH. Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep 2009; 11:87-93; http://dx.doi. org/10.1007/s11912-009-0014-6
22. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162-79; http://dx.doi. org/10.1111/j.1600-065X.2008.00602.x
23. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses. Cancer Res 2004; 64:5839-49; http://dx.doi.org/10.1158/0008-5472.CAN-04-0465
24. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003; 171:1232-9.
25. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109:1568-73; http://dx.doi.org/10.1182/blood-2006-06-031856
26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; http:// dx.doi.org/10.1038/nri2506
27. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160:5729-34.
28. Harari O, Liao JK. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des 2004; 10:893-8; http://dx.doi. org/10.2174/1381612043452893
29. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188:97-113; http://dx.doi.org/10.1034/j.1600-065X.2002.18809.x
30. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007; 13:5243-8; http://dx.doi.org/10.1158/1078-0432.CCR-07-0182
31. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; http:// dx.doi.org/10.1038/nm1609
32. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumorassociated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175:4583-92.
33. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 2007; 67:11021-8; http://dx.doi.org/10.1158/0008-5472.CAN-07-2593
34. Szuster-Ciesielska A, Hryciuk-Umer E, Stepulak A, Kupisz K, Kandefer-Szersze M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol 2004; 43:252-8; http://dx.doi.org/10.1080/02841860410029708
35. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61:4756-60.
36. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989-99.
37. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 2001; 11:173-86
38. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, et al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res 2008; 68:3467-75; http://dx.doi.org/10.1158/0008-5472.CAN-07-5301
39. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198:1741-52; http://dx.doi.org/10.1084/jem.20022227
40. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35; http://dx.doi.org/10.1016/j. ccr.2007.12.004
41. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68-77; http://dx.doi.org/10.1158/0008-5472.CAN-09-2587
42. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009; 183:937-44; http://dx.doi.org/10.4049/jimmunol. 0804253
43. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-83.
44. Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006; 66:6807-15; http://dx.doi.org/10.1158/0008-5472.CAN-05-3755
45. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439-49; http://dx.doi.org/10.1158/0008-5472.CAN-07-6621
46. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299
47. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancerexpanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182:240-9.
48. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007; 109:4336-42; http:// dx.doi.org/10.1182/blood-2006-09-046201
49. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, et al. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 2010; 40:3347-57; http:// dx.doi.org/10.1002/eji.201041037
50. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (Type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005; 202:1627-33; http://dx.doi.org/10.1084/jem.20051381
51. Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res 2003; 63:3058-60.
52. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004; 64:1675-86; http://dx.doi. org/10.1158/0008-5472.CAN-03-0160
53. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25:911-20; http://dx.doi.org/10.1038/nbt1323
54. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; http://dx.doi. org/10.1038/nm1100
55. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66:9299-307; http://dx.doi.org/10.1158/0008-5472.CAN-06-1690
56. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63:4441-9.
57. Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, et al. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol 2011; 11:890-8; http://dx.doi.org/10.1016/j. intimp.2011.01.007
58. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009; 182:1818-28; http://dx.doi.org/10.4049/jimmunol. 0802430
59. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201:1503-17; http://dx.doi.org/10.1084/ jem.20042592
60. Wu H, Tao N, Liu X, Li X, Tang J, Ma C, et al. Polysaccharide from Lentinus edodes inhibits the immunosuppressive function of myeloidderived suppressor cells. PLoS One 2012; 7:e51751; http://dx.doi.org/10.1371/journal. pone.0051751
61. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007; 42:93-126; http://dx.doi.org/10.1007/1-4020-5688-5_4
62. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; http://dx.doi. org/10.1158/0008-5472.CAN-06-4174
63. Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M, Toth B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 2007; 7:140-51; http://dx.doi.org/10.1016/j. intimp.2006.09.021
64. Veltman JD, Lambers ME, Van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010; 10:464; http://dx.doi.org/10.1186/1471-2407-10-464
65. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; http://dx.doi. org/10.1084/jem.20061104
66. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005; 102:4185-90; http:// dx.doi.org/10.1073/pnas.0409783102
67. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007; 12:230-8; http://dx.doi.org/10.1016/j. ccr.2007.08.004
68. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169:3892-9.
69. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hämmerling GJ. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167:5247-53.
70. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012; 188:1592-9; http://dx.doi. org/10.4049/jimmunol.1101304
71. Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 2007; 13:345-8; http://dx.doi.org/10.1097/PPO.0b013e31815a7b69
72. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13:4840-8; http://dx.doi.org/10.1158/1078-0432.CCR-07-0409
73. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67:11438-46; http://dx.doi.org/10.1158/0008-5472.CAN-07-1882
74. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 2008; 8:592-603; http://dx.doi.org/10.1038/nrc2442
75. Miller KD, Sweeney CJ, Sledge GW Jr. Can tumor angiogenesis be inhibited without resistance? EXS 2005; 94:95-112; http://dx.doi. org/10.1007/3-7643-7311-3_7
76. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6:4768-75.
77. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010; 120:3843-54; http://dx.doi.org/10.1172/ JCI42059
78. Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer 2012; 131:891-901; http://dx.doi.org/10.1002/ ijc.26451
79. Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 2012; 188:5365-76; http://dx.doi.org/10.4049/jimmunol.1103553
80. Roth F, De La Fuente AC, Vella JL, Zoso A, Inverardi L, Serafini P. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012; 72:1373-83; http://dx.doi.org/10.1158/0008-5472.CAN-11-2772
81. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116:2777-90; http://dx.doi.org/10.1172/JCI28828
82. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182:6562-8; http://dx.doi.org/10.4049/jimmunol. 0803831
83. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation of myeloidderived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 2012; 5:205-15; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0247
84. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/ CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
85. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-61; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690
86. Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19:57-64; http://dx.doi.org/10.1038/nm.2999
87. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383-91; http://dx.doi. org/10.1007/s00262-012-1343-0.
88. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94; http://dx.doi. org/10.1158/1078-0432.CCR-10-0733
89. Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 2012; 189:5147-54; http://dx.doi. org/10.4049/jimmunol.1200274